Protein Sequencing by Expansion (ProSE™)
by Expansion (ProSE™)
proteome sequencing
Introducing ProSE™
1
Technology
ProSE™ will revolutionize proteomics by delivering unprecedented precision, scalability, and accessibility.
2025
Sample Preparation
Molecular Expansion
Amino Acid Sequencing
1
Glyphic biotechnologies
1
Sample Peparation
REAGENT KITS FUNCTIONALIZE PEPTIDES
2
MOLECULAR EXPANSION
ORDERED EXPANSION OF AMINO ACIDS
3
AMINO ACID SEQUENCING
UNBIASED DISCRIMINATION OF ALL 20 AAs + PTMs
Glyphic Biotechnologies

Glyphic Biotechnologies, Inc. is developing the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 AAs and PTMs accurately with single molecule sensitivity.
Since 2021

Protein Sequencing by Expansion (ProSE™)
Founded in 2021 and headquartered in Berkeley (CA), Glyphic Biotechnologies exists to fundamentally rewrite the rules of proteomics.
We believe proteome sequencing will be one of the defining technologies of the 21st century. The precision, scalability, and accessibility of Glyphic’s Protein Sequencing by Expansion (ProSE™) will enable the development of critical first-in-class therapies, and deeper insights into life itself.
Patent Strategy
Glyphic pioneers innovation and holds seminal IP in protein sequencing.
Careers
Open positions

The next great chapter of scientific discovery will be written in ProSE™
Contact
Information
Get in Touch!
Compose the Future with Us